Cystic Fibrosis News Today Weekly Digest

Cystic Fibrosis Weekly Update Contents: 5,000 Expected to Attend Cystic Fibrosis Conference, NACFC 2019, in Nashville Patient-derived Mini-organs Work as ‘Avatars’ to Test CF Treatments Vertex Partners with Ribometrix to Discover RNA-targeted Therapies 5,000 Expected to Attend Cystic Fibrosis Conference, NACFC 2019, in Nashville Oct 07, 2019 07:00 am | Larry Luxner The Western Hemisphere’s largest gathering of experts in cystic fibrosis gets underway later this month in Nashville, Tennessee — site of the 33rd annual North American Cystic Fibrosis Conference (NACFC). The Oct. 31–Nov. 2 event, sponsored by the Cystic Fibrosis Foundation (CFF), will attract more than 5,000 delegates to discuss a disease that affects between 70,000 […] The post 5,000 Expected to Attend Cystic Fibrosis Conference, NACFC 2019, in Nashville appeared first on Cystic Fibrosis News Today. Read More Patient-derived Mini-organs Work as ‘Avatars’ to Test CF Treatments Oct 04, 2019 07:30 am | Marta Figueiredo Researchers in Australia are growing mini gut and lung “avatars” derived from cells of children with cystic fibrosis (CF) to predict their response to current and potential medications. This platform may revolutionize the way clinicians treat CF patients, reducing the “trial-and-error” phase from the treatment process, and helping to develop personalized medicine. CF can be […] The post Patient-derived Mini-organs Work as ‘Avatars’ to Test CF Treatments appeared first on Cystic Fibrosis News Today. Read More Vertex Partners with Ribometrix to Discover RNA-targeted Therapies Oct 03, 2019 07:00 am | Ana Pena, PhD Vertex Pharmaceuticals has entered a strategic collaboration with Ribometrix to discover potential RNA-targeted therapies for serious diseases. Vertex is a leader in the market of CFTR modulators for cystic fibrosis (CF), and is the developer of Kalydeco (ivacaftor), Orkambi (ivacaftor/lumacaftor), and Symdeko (tezacaftor/ivacaftor combination therapy), three approved CF therapies. The new partnership will lean on Ribometrix’s proprietary discovery platform for […] The post Vertex Partners with Ribometrix to Discover RNA-targeted Therapies appeared first on Cystic Fibrosis News Today. Read More Recent News Hexoskin Smart Shirt Can Accurately Assess Respiratory Function, May Be Tool in CF, Study Shows ‘I’m Better at Being Sick Than You Are’: Chronic Illness Is Not a Competition IL-1 Receptor Inhibition a Potential Strategy to Block Mucus Build-up in Early CF, Study Suggests An Obstacle on My Chosen Career Path Led to an Identity Crisis Public Encouraged to Vote for 2 Students with CF to Receive $22K AbbVie Scholarships